NCT01451398
Completed
Phase 3
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Technosphere Inhalation Powder in Insulin Naïve Subjects With Type 2 Diabetes Mellitus Poorly Controlled With Oral Antidiabetic Agents Over a 24 Week Treatment Period
ConditionsType 2 Diabetes
Overview
- Phase
- Phase 3
- Intervention
- Technosphere® Insulin
- Conditions
- Type 2 Diabetes
- Sponsor
- Mannkind Corporation
- Enrollment
- 353
- Primary Endpoint
- Change From Baseline to Week 24 in HbA1c
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Insulin-naive subjects with Type 2 Diabetes Mellitus who are sub-optimally controlled on either maximum tolerated dose of metformin or maximum tolerated dose of metformin plus one or two other oral anti-diabetic medications will have either Prandial Technosphere® Insulin or Technosphere Powder (placebo) added to their oral antidiabetic drugs.
Investigators
Eligibility Criteria
Inclusion Criteria
- •HbA1c \> or = to 7.5% and \< or = to 10.0%
- •Body mass index (BMI) \< or = to 45 kg/m2
- •Non smoker for at least 6 months before Screening
- •Clinical diagnosis of type 2 diabetes mellitus for more than 12 months
- •Currently receiving as diabetes treatment only metformin or 2 or more OADs and on stable doses for at least 3 months before enrollment
- •Subjects receiving metformin must be on at least 1.5gm daily, or up to the maximum tolerated dose
- •Subjects treated with a sulfonylurea must be on at least 50% of the total maximum approved dose for a given agent
- •Subjects receiving a DPP-4 inhibitor must receive the maximum approved dose specific for that agent
- •Metiglinide and alpha-glucoside inhibitors must be taken at the highest tolerated dose within the approved dose range
- •No previous or current treatment with insulin, except during an acute illness, gestational diabetes, or at time of initial diagnosis of diabetes
Exclusion Criteria
- •History of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or any other clinically important pulmonary disease (eg, pulmonary fibrosis)
- •Any clinically significant radiological findings on screening chest x-ray
- •Use of medications for asthma, COPD, or any other chronic respiratory conditions
- •Evidence of serious complications of diabetes (proliferative retinopathy, autonomic neuropathy with symptoms of gastroparesis or cardiac arrhythmia; sensory neuropathy that makes manipulation of the Gen2C inhaler difficult)
- •Renal disease or renal dysfunction
- •Significant cardiovascular dysfunction or history thereof within 12 months of screening; serious arrhythmia, treatment with medications to control/treat arrhythmias; myocardial infarction; cardiac surgery; history of valvular heart disease
- •Previous or current use of amiodarone
- •Treatment with glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones (TZD), or weight loss drugs (eg, sibutramine, orlistat) within 3 months of screening
- •History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening
- •History of recent blood transfusion (within previous 3 months) or diagnosis of hemoglobinopathies that may affect HbA1c measurements
Arms & Interventions
TI inhalation powder
Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
Intervention: Technosphere® Insulin
Technosphere powder
Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
Intervention: Technosphere Powder
Outcomes
Primary Outcomes
Change From Baseline to Week 24 in HbA1c
Time Frame: Baseline to Week 24
Efficacy as measured by change in glycated hemoglobin (HbA1c) at Week 24
Secondary Outcomes
- Total Hypoglycemia Event Rate(Baseline to Week 24)
- Mean 7-point Glucose Baseline Values(Baseline)
- Proportion of Responders Achieving HbA1c <= 6.5%(Week 24)
- FPG Change From Baseline to Week 24(Baseline to Week 24)
- Time to Rescue(Baseline to Week 24)
- Severe Hypoglycemia Event Rate(Baseline to Week 24)
- Change in Body Weight From Baseline to Week 24(Baseline to Week 24)
- FEV1 Change From Baseline to Week 24(Baseline to Week 24)
- Proportion of Responders Achieving HbA1c <= 7.0%(Week 24)
- Proportion of Subjects Requiring Rescue Therapy(Baseline to Week 24)
- Mean 7-point Glucose Week 24 Values(Week 24)
- Incidence of Total Hypoglycemia(Baseline to Week 24)
- Incidence of Severe Hypoglycemia(Baseline to Week 24)
Similar Trials
Completed
Phase 3
A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00351585Novartis39
Completed
Phase 2
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To BoneHealth Condition 1: null- Neoplasm MetastasisPalliative CareCTRI/2011/05/001754Pfizer Limited58
Completed
Not Applicable
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To BoneC795-C795 Secondary malignant neoplasm of bone and bone marrowSecondary malignant neoplasm of bone and bone marrowPER-020-09PFIZER S.A.,
Active, not recruiting
Not Applicable
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer. Final Protocol dated 2007-06-19, Protocol Amendment 1 dated 2007-08-06, Protocol Amendment 2 dated 2007-08-16, Protocol Amendment 3 dated 2007-10-31, Protocol Amendment 4 dated 2007-12-17, Protocol Amendment 5 dated 2008-04-14, Protocol Amendment 6 dated 2008-09-09, Protocol Amendment 7 dated 2009-04-15Prostate cancerEUCTR2007-003470-26-SEActive Biotech Research AB200
Recruiting
Not Applicable
AtTEnd – Atezolizumab Trial in Endometrial cancerKCT0005761CHA University Ilsan Medical Center550